Key result
NFAT blocker A-285222 prevents hyperglycemia-induced osteopontin expression in diabetic mice.
Why the study?
Hyperglycemia activates NFAT in arteries ex vivo, but its activation in vivo and role in vascular complications of diabetes were unclear.
Answers are grounded in this paper and cite their sources.
Identifies a glucose-sensitive transcription pathway via NFAT that regulates osteopontin expression, revealing a potential novel molecular mechanism underlying vascular complications of diabetes.
Objective— Hyperglycemia is a recognized risk factor for cardiovascular disease in diabetes. Recently, we reported that high glucose activates the Ca 2+ /calcineurin-dependent transcription factor nuclear factor of activated T cells (NFAT) in arteries ex vivo. Here, we sought to determine whether hyperglycemia activates NFAT in vivo and whether this leads to vascular complications. Methods and Results— An intraperitoneal glucose-tolerance test in mice increased NFATc3 nuclear accumulation in vascular smooth muscle. Streptozotocin-induced diabetes resulted in increased NFATc3 transcriptional activity in arteries of NFAT-luciferase transgenic mice. Two NFAT-responsive sequences in the osteopontin (OPN) promoter were identified. This proinflammatory cytokine has been shown to exacerbate atherosclerosis and restenosis. Activation of NFAT resulted in increased OPN mRNA and protein in native arteries. Glucose-induced OPN expression was prevented by the ectonucleotidase apyrase, suggesting a mechanism involving the release of extracellular nucleotides. The calcineurin inhibitor cyclosporin A or the novel NFAT blocker A-285222 prevented glucose-induced OPN expression. Furthermore, diabetes resulted in higher OPN expression, which was significantly decreased by in vivo treatment with A-285222 for 4 weeks or prevented in arteries from NFATc3 −/− mice. Conclusions— These results identify a glucose-sensitive transcription pathway in vivo, revealing a novel molecular mechanism that may underlie vascular complications of diabetes.
No takes yet. Share an insight, caveat, or question.
Berglund et al. (2009) studied Diabetes-Induced Hyperglycemia. A-285222 (NFAT blocker) was evaluated on Osteopontin (OPN) expression and NFATc3 activation. In mice, diabetes-induced hyperglycemia activated the NFAT pathway and increased osteopontin expression, which was prevented by a 4-week in vivo treatment with the NFAT blocker A-285222.
Synapse has enriched 10 related papers. Consider them for comparative context: